Individualized Comprehensive Treatment for Advanced Hepatocellular Carcinoma

This project is a prospective, multi-center, multi-cohort exploratory clinical study. It focuses on patients with advanced hepatocellular carcinoma who experience disease progression after first-line standard therapy. Based on different patterns of disease progression, patients will receive relevant systemic treatments, either with or without local interventional therapy. The primary endpoint is progression-free survival (PFS), while secondary endpoints include overall survival (OS), 1-year OS rate, objective response rate (ORR), disease control rate (DCR), duration of remission (DOR), and saf

Trial Details

NCT ID
NCT06893887
Phase
NA
Sponsor
Nanjing Tianyinshan Hospital
Status
RECRUITING
Cancer Type
Liver Cancer
Interventions
  • FOLFOX4
  • Adebrelimab
  • Apatinib
  • Icaritin
  • SHR-1701
  • QL1706
Locations (sample)
  • Nanjing, Jiangsu, China|32.06167,118.77778

Key Eligibility Criteria

  • Age ≥18 years old, male or female
  • Hepatocellular carcinoma patients diagnosed by cytology or tissue puncture, or who meet clinical diagnostic criteria and cannot be treated with rad…
  • Disease progression after first-line targeted combined immune system therapy (as per RECIST1.1 criteria)
  • Life expectancy exceeds 3 months

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Liver Cancer Trials on Trialify →